The Down Under medical sector is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in clinical trials for treating obesity. This medication https://directmysocial.com/story6549078/retatrutide-australia-australia-a-new-hope-for-weight-loss